Unifive: Phase III discontinued

sanofi-aventis discontinued development of Unifive, which was in Phase III testing, due to a reprioritization of its R&D portfolio. Resources will be reallocated from Unifive to Hexaxim, a hexavalent vaccine in Phase III testing to prevent the same 5 infections, plus polio. ...